Source: recombinant E.coli
Storage conditions: Store below -15°C, Protect Products from light
Product Introduction
This is a new generation glucagon-like peptide (GLP-1) receptor agonist, which reduces glucagon secretion by stimulating insulin secretion. Compared with liraglutide, its fat chain is longer, its hydrophobicity is increased, it is closely bound to albumin, covers the DPP-4 enzymatic hydrolysis site, and can also reduce renal excretion, prolong the biological half-life, and achieve a long cycle effect, the action cycle can reach one week. There are very good clinical effects in reducing blood sugar, weight loss, cardiovascular benefits, and other aspects.
Product focus quality analysis
Product advantages
- API and biosimilar declaration in accordance with GMP;
- Complete quality molecular and process documentation: Ready for US-DMF registration;
- Stable quality: Mass production(10kg/Batch), can ensure stable and continuous batch production; The product varies from batch to batch and the quality is stable.